Squarepoint Ops LLC Buys 229,858 Shares of Hologic, Inc. (NASDAQ:HOLX)

Squarepoint Ops LLC lifted its holdings in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 657.8% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 264,800 shares of the medical equipment provider's stock after purchasing an additional 229,858 shares during the quarter. Squarepoint Ops LLC owned about 0.12% of Hologic worth $19,089,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of HOLX. Principal Financial Group Inc. raised its stake in shares of Hologic by 0.6% during the 4th quarter. Principal Financial Group Inc. now owns 271,152 shares of the medical equipment provider's stock worth $19,547,000 after purchasing an additional 1,606 shares in the last quarter. Nisa Investment Advisors LLC raised its stake in shares of Hologic by 44.7% during the 4th quarter. Nisa Investment Advisors LLC now owns 63,744 shares of the medical equipment provider's stock worth $4,595,000 after purchasing an additional 19,688 shares in the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management raised its stake in shares of Hologic by 11.4% during the 4th quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 68,427 shares of the medical equipment provider's stock worth $4,933,000 after purchasing an additional 6,986 shares in the last quarter. Groupama Asset Managment raised its stake in shares of Hologic by 63.4% during the 4th quarter. Groupama Asset Managment now owns 54,214 shares of the medical equipment provider's stock worth $3,918,000 after purchasing an additional 21,037 shares in the last quarter. Finally, Olstein Capital Management L.P. raised its stake in shares of Hologic by 5.9% during the 4th quarter. Olstein Capital Management L.P. now owns 90,000 shares of the medical equipment provider's stock worth $6,488,000 after purchasing an additional 5,000 shares in the last quarter. Institutional investors own 94.73% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the company. Morgan Stanley dropped their price objective on Hologic from $77.00 to $65.00 and set an "equal weight" rating on the stock in a research note on Monday, May 5th. Raymond James restated an "outperform" rating and issued a $71.00 price target (down previously from $90.00) on shares of Hologic in a research note on Friday, May 2nd. Leerink Partnrs cut Hologic from a "strong-buy" rating to a "hold" rating in a research note on Thursday, February 6th. Stephens dropped their price target on Hologic from $77.00 to $70.00 and set an "overweight" rating on the stock in a research note on Tuesday, May 13th. Finally, Needham & Company LLC restated a "hold" rating on shares of Hologic in a research note on Friday, May 2nd. Twelve equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $77.42.

Insider Transactions at Hologic

In related news, Director Martin D. Madaus bought 5,445 shares of Hologic stock in a transaction dated Wednesday, May 7th. The shares were bought at an average cost of $55.24 per share, with a total value of $300,781.80. Following the acquisition, the director now owns 5,445 shares in the company, valued at $300,781.80. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. 1.88% of the stock is currently owned by insiders.

Hologic Price Performance

Shares of HOLX traded up $0.52 during trading hours on Tuesday, hitting $54.80. 527,232 shares of the company were exchanged, compared to its average volume of 2,138,613. The company has a market cap of $12.21 billion, a price-to-earnings ratio of 17.29, a P/E/G ratio of 2.14 and a beta of 0.54. Hologic, Inc. has a fifty-two week low of $51.90 and a fifty-two week high of $84.67. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52. The firm's fifty day moving average is $58.02 and its 200 day moving average is $66.26.

Hologic (NASDAQ:HOLX - Get Free Report) last released its earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.01. The company had revenue of $1.01 billion for the quarter, compared to analyst estimates of $1 billion. Hologic had a return on equity of 19.72% and a net margin of 18.42%. Hologic's quarterly revenue was down 1.2% on a year-over-year basis. During the same period in the prior year, the firm posted $1.03 EPS. On average, equities analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.